{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:29:01Z","timestamp":1792146541258,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"DOI":"10.1007\/s13577-025-01274-z","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:45:55Z","timestamp":1760456755000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long non-coding RNA FEZF1-AS1 suppresses ferroptosis in multiple myeloma cells through KIAA1429-mediated m6A modification"],"prefix":"10.1007","volume":"38","author":[{"given":"Qing","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peijin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0145-9158","authenticated-orcid":false,"given":"Mingyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"1274_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, et al. Diagnosis and management of multiple myeloma: a review. JAMA. 2022;327:464\u201377.","journal-title":"JAMA"},{"key":"1274_CR2","volume":"9","author":"SA Padala","year":"2021","unstructured":"Padala SA, Barsouk A, Barsouk A, et al. Epidemiology, staging, and management of multiple myeloma. Med Sci. 2021;9: 3.","journal-title":"Med Sci"},{"key":"1274_CR3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV. Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99:1802\u201324.","journal-title":"Am J Hematol"},{"key":"1274_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","volume":"14","author":"AJ Devasia","year":"2024","unstructured":"Devasia AJ, Chari A, Lancman G. Bispecific antibodies in the treatment of multiple myeloma. Blood Cancer J. 2024;14:158.","journal-title":"Blood Cancer J"},{"key":"1274_CR5","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1007\/s11864-024-01250-z","volume":"25","author":"P Li","year":"2024","unstructured":"Li P, Lyu T. Research progress on ferroptosis in multiple myeloma. Curr Treat Options Oncol. 2024;25:1276\u201382.","journal-title":"Curr Treat Options Oncol"},{"key":"1274_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.743006","volume":"11","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Huang Z, Peng H. Molecular mechanisms of ferroptosis and its roles in hematologic malignancies. Front Oncol. 2021;11: 743006.","journal-title":"Front Oncol"},{"key":"1274_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834681","volume":"12","author":"H Lan","year":"2022","unstructured":"Lan H, Gao Y, Zhao Z, Mei Z, Wang F. Ferroptosis: redox imbalance and hematological tumorigenesis. Front Oncol. 2022;12: 834681.","journal-title":"Front Oncol"},{"key":"1274_CR8","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202009045","volume":"220","author":"MC Bridges","year":"2021","unstructured":"Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220: e202009045.","journal-title":"J Cell Biol"},{"key":"1274_CR9","doi-asserted-by":"publisher","first-page":"142","DOI":"10.3892\/or.2024.8801","volume":"52","author":"N Zhang","year":"2024","unstructured":"Zhang N, Wen K. The role of lncRNA binding to RNA-binding proteins to regulate mRNA stability in cancer progression and drug resistance mechanisms (review). Oncol Rep. 2024;52:142.","journal-title":"Oncol Rep"},{"key":"1274_CR10","doi-asserted-by":"publisher","DOI":"10.1042\/BSR20191202","volume":"39","author":"C Shi","year":"2019","unstructured":"Shi C, Sun L, Song Y. FEZF1-AS1: a novel vital oncogenic lncRNA in multiple human malignancies. Biosci Rep. 2019;39: BSR20191202.","journal-title":"Biosci Rep"},{"key":"1274_CR11","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1002\/hon.3157","volume":"41","author":"X Long","year":"2023","unstructured":"Long X, Wen F, Li J, Huang X. Lncrna FEZF1-AS1 accelerates multiple myeloma progression by regulating IGF2BP1\/BZW2 signaling. Hematol Oncol. 2023;41:694\u2013703.","journal-title":"Hematol Oncol"},{"key":"1274_CR12","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.dld.2022.12.005","volume":"55","author":"S Chen","year":"2023","unstructured":"Chen S, Xia H, Sheng L. WTAP-mediated m6A modification on circCMTM3 inhibits hepatocellular carcinoma ferroptosis by recruiting IGF2BP1 to increase PARK7 stability. Dig Liver Dis. 2023;55:967\u201381.","journal-title":"Dig Liver Dis"},{"key":"1274_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111221","volume":"120","author":"F Yao","year":"2024","unstructured":"Yao F, Zhao Y, Wang G, et al. Exosomal lncRNA ROR1-AS1 from cancer-associated fibroblasts inhibits ferroptosis of lung cancer cells through the IGF2BP1\/SLC7A11 signal axis. Cell Signal. 2024;120: 111221.","journal-title":"Cell Signal"},{"key":"1274_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.778","volume":"12","author":"L Liu","year":"2022","unstructured":"Liu L, He J, Sun G, et al. The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clin Transl Med. 2022;12: e778.","journal-title":"Clin Transl Med"},{"key":"1274_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s40364-023-00499-0","volume":"11","author":"TY Zhu","year":"2023","unstructured":"Zhu TY, Hong LL, Ling ZQ. Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark Res. 2023;11:62.","journal-title":"Biomark Res"},{"key":"1274_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s12943-022-01500-4","volume":"21","author":"Y An","year":"2022","unstructured":"An Y, Duan H. The role of m6A RNA methylation in cancer metabolism. Mol Cancer. 2022;21:14.","journal-title":"Mol Cancer"},{"key":"1274_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/MOH.0000000000000741","volume":"30","author":"WJ Wang","year":"2023","unstructured":"Wang WJ, Xu TT, Bao J. N6-methyladenosine in hematological malignancies: a concise review. Curr Opin Hematol. 2023;30:4\u201313.","journal-title":"Curr Opin Hematol"},{"key":"1274_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.3390\/cancers14020332","volume":"14","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Peng H. The role of N(6)-methyladenosine (m(6)A) methylation modifications in hematological malignancies. Cancers (Basel). 2022;14:332.","journal-title":"Cancers (Basel)"},{"key":"1274_CR19","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/biom14101319","volume":"14","author":"J Huang","year":"2024","unstructured":"Huang J, Guo J, Jia R. N6-methyladenosine methyltransferase component KIAA1429 is a potential target of cancer therapy. Biomolecules. 2024;14:10.","journal-title":"Biomolecules"},{"key":"1274_CR20","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s10565-024-09904-2","volume":"40","author":"Y Wu","year":"2024","unstructured":"Wu Y, Luo Y, Yao X, et al. KIAA1429 increases FOXM1 expression through YTHDF1-mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myeloma. Cell Biol Toxicol. 2024;40:58.","journal-title":"Cell Biol Toxicol"},{"key":"1274_CR21","first-page":"5320","volume":"13","author":"Y Wu","year":"2023","unstructured":"Wu Y, Li H, Huang Y, Chen Q. Silencing of m(6)A methyltransferase KIAA1429 suppresses the progression of non-small cell lung cancer by promoting the p53 signaling pathway and ferroptosis. Am J Cancer Res. 2023;13:5320\u201333.","journal-title":"Am J Cancer Res"},{"key":"1274_CR22","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.canlet.2021.12.002","volume":"526","author":"Y Liao","year":"2022","unstructured":"Liao Y, Yang M, Wang K, Wang Y, Zhong B, Jiang N. Deubiquitinating enzyme OTUB1 in immunity and cancer: good player or bad actor? Cancer Lett. 2022;526:248\u201358.","journal-title":"Cancer Lett"},{"key":"1274_CR23","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1111\/cas.14876","volume":"112","author":"HH Zhang","year":"2021","unstructured":"Zhang HH, Li C, Ren JW, et al. OTUB1 facilitates bladder cancer progression by stabilizing ATF6 in response to endoplasmic reticulum stress. Cancer Sci. 2021;112:2199\u2013209.","journal-title":"Cancer Sci"},{"key":"1274_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2023.166767","volume":"1869","author":"A Sheryazdanova","year":"2023","unstructured":"Sheryazdanova A, Amoedo ND, Dufour S, Impens F, Rossignol R, Sablina A. The deubiquitinase OTUB1 governs lung cancer cell fitness by modulating proteostasis of OXPHOS proteins. Biochim Biophys Acta (BBA). 2023;1869: 166767.","journal-title":"Biochim Biophys Acta (BBA)"},{"key":"1274_CR25","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1038\/s41418-020-00700-z","volume":"28","author":"D Zhu","year":"2021","unstructured":"Zhu D, Xu R, Huang X, et al. Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1. Cell Death Differ. 2021;28:1773\u201389.","journal-title":"Cell Death Differ"},{"key":"1274_CR26","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1182\/blood.2020005199","volume":"137","author":"Y Xu","year":"2021","unstructured":"Xu Y, Xu M, Tong J, et al. Targeting the Otub1\/c-Maf axis for the treatment of multiple myeloma. Blood. 2021;137:1478\u201390.","journal-title":"Blood"},{"key":"1274_CR27","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"1274_CR28","doi-asserted-by":"publisher","first-page":"D92","DOI":"10.1093\/nar\/gkt1248","volume":"42","author":"JH Li","year":"2014","unstructured":"Li JH, Liu S, Zhou H, Qu LH, Yang JH. StarBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92\u20137.","journal-title":"Nucleic Acids Res"},{"key":"1274_CR29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1186\/1471-2105-12-489","volume":"12","author":"UK Muppirala","year":"2011","unstructured":"Muppirala UK, Honavar VG, Dobbs D. Predicting RNA-protein interactions using only sequence information. BMC Bioinformatics. 2011;12:489.","journal-title":"BMC Bioinformatics"},{"key":"1274_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkw104","volume":"44","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Zeng P, Li YH, Zhang Z, Cui Q. SRAMP: prediction of mammalian N6-methyladenosine (m6A) sites based on sequence-derived features. Nucleic Acids Res. 2016;44: e91.","journal-title":"Nucleic Acids Res"},{"key":"1274_CR31","doi-asserted-by":"publisher","first-page":"D719","DOI":"10.1093\/nar\/gkab962","volume":"50","author":"X Wang","year":"2022","unstructured":"Wang X, Li Y, He M, et al. UbiBrowser 2.0: a comprehensive resource for proteome-wide known and predicted ubiquitin ligase\/deubiquitinase-substrate interactions in eukaryotic species. Nucleic Acids Res. 2022;50:D719\u201328.","journal-title":"Nucleic Acids Res"},{"key":"1274_CR32","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1093\/oncolo\/oyad306","volume":"29","author":"A Rafae","year":"2024","unstructured":"Rafae A, van Rhee F, Al Hadidi S. Perspectives on the treatment of multiple myeloma. Oncologist. 2024;29:200\u201312.","journal-title":"Oncologist"},{"key":"1274_CR33","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1016\/j.biopha.2018.04.094","volume":"103","author":"QY Li","year":"2018","unstructured":"Li QY, Chen L, Hu N, Zhao H. Long non-coding RNA FEZF1-AS1 promotes cell growth in multiple myeloma via miR-610\/Akt3 axis. Biomed Pharmacother. 2018;103:1727\u201332.","journal-title":"Biomed Pharmacother"},{"key":"1274_CR34","doi-asserted-by":"publisher","first-page":"1026153","DOI":"10.3389\/fonc.2022.1026153","volume":"12","author":"J Qin","year":"2022","unstructured":"Qin J, Sharma A, Wang Y, et al. Systematic discrimination of the repetitive genome in proximity of ferroptosis genes and a novel prognostic signature correlating with the oncogenic lncRNA CRNDE in multiple myeloma. Front Oncol. 2022;12:1026153.","journal-title":"Front Oncol"},{"key":"1274_CR35","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.17305\/bb.2024.10313","volume":"24","author":"H Chen","year":"2024","unstructured":"Chen H, Zhu P, Zhu D, Jin J, Yang Q, Han X. Role and mechanism of KIAA1429 in regulating cellular ferroptosis and radioresistance in colorectal cancer. Biomol Biomed. 2024;24:1669\u201381.","journal-title":"Biomol Biomed"},{"key":"1274_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2023.101745","volume":"36","author":"K Xu","year":"2023","unstructured":"Xu K, Dai X, Yue J. M(6)A methyltransferase KIAA1429 accelerates oral squamous cell carcinoma via regulating glycolysis and ferroptosis. Transl Oncol. 2023;36: 101745.","journal-title":"Transl Oncol"},{"key":"1274_CR37","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1158\/0008-5472.CAN-18-3037","volume":"79","author":"T Liu","year":"2019","unstructured":"Liu T, Jiang L, Tavana O, Gu W. The deubiquitylase OTUB1 mediates ferroptosis via stabilization of SLC7A11. Cancer Res. 2019;79:1913\u201324.","journal-title":"Cancer Res"},{"key":"1274_CR38","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1007\/s13238-020-00789-5","volume":"12","author":"P Koppula","year":"2021","unstructured":"Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11\/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein Cell. 2021;12:599\u2013620.","journal-title":"Protein Cell"},{"key":"1274_CR39","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1007\/s10495-023-01909-2","volume":"29","author":"W Zhang","year":"2024","unstructured":"Zhang W, Li Q, Zhang Y, et al. Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis. Apoptosis. 2024;29:412\u201323.","journal-title":"Apoptosis"},{"key":"1274_CR40","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s12964-020-00676-w","volume":"19","author":"T Sun","year":"2021","unstructured":"Sun T, Xu Y, Xu Z, et al. Inhibition of the Otub1\/c-Maf axis by the herbal acevaltrate induces myeloma cell apoptosis. Cell Commun Signal. 2021;19:24.","journal-title":"Cell Commun Signal"},{"key":"1274_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834729","volume":"12","author":"X Liang","year":"2022","unstructured":"Liang X, Hu C, Han M, et al. Solasonine inhibits pancreatic cancer progression with involvement of ferroptosis induction. Front Oncol. 2022;12: 834729.","journal-title":"Front Oncol"},{"key":"1274_CR42","doi-asserted-by":"publisher","first-page":"12636","DOI":"10.1080\/21655979.2021.2011633","volume":"12","author":"X Zhao","year":"2021","unstructured":"Zhao X, Zhou M, Yang Y, Luo M. The ubiquitin hydrolase OTUB1 promotes glioma cell stemness via suppressing ferroptosis through stabilizing SLC7A11 protein. Bioengineered. 2021;12:12636\u201345.","journal-title":"Bioengineered"},{"key":"1274_CR43","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1002\/cbin.12211","volume":"48","author":"Y Liu","year":"2024","unstructured":"Liu Y, Bai Q, Pang N, Xue J. TCF12 induces ferroptosis by suppressing OTUB1-mediated SLC7A11 deubiquitination to promote cisplatin sensitivity in oral squamous cell carcinoma. Cell Biol Int. 2024;48:1649\u201363.","journal-title":"Cell Biol Int"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01274-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01274-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01274-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T02:11:55Z","timestamp":1760494315000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01274-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":43,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,11]]}},"alternative-id":["1274"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01274-z","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"178"}}